News
HST Collects relevant news from a variety of sources, for your convenience. Select a story from below, or use our search feature to find stories of interest.

AIDS researchers say they have gained edge over virus
SAPA-AFP
2003-02-20

Development of new drugs and improved, simplified therapies have given researchers an edge over the deadly AIDS virus, experts told a conference here. It's an exciting and important year for therapy, John Mellors, of the University of Pittsburg School of Medicine, told the 10th annual conference on retroviruses on Tuesday. The cocktail of drugs that since the mid-1990s has transformed the HIV-AIDS infection from a death sentence to a chronic illness is about to expand, some 4,000 AIDS specialists gathered here for the week-long conference were told. Researchers are testing drugs that would prevent the virus from attacking human cells and growing inside the body, Mellors said. Six such drugs are ready for human testing and another dozen are almost ready for clinical tests, he said. Anti-AIDS therapies have become simpler and their success rates have improved to 75-85 percent from 50-60 percent only a few years ago, Mellors said. Today, instead of 10 to 20 pills taken twice or three times a day, therapies consist of two or three pills taken in the morning or evening, or one pill taken twice a day, he said.The simplicity is all the more important because it allows treatment in developing nations, he said. HAART (Highly active antiretroviral therapy) can be given in a hut, which makes it very effective at fighting AIDS in developing nations, Mellors said. (Source:SAPA-AFP, 12 February 2003)

Development of new drugs and improved, simplified therapies have given researchers an edge over the deadly AIDS virus, experts told a conference here.

It's an exciting and important year for therapy, John Mellors, of the University of Pittsburg School of Medicine, told the 10th annual conference on retroviruses on Tuesday.

It seems for the first time that we are beginning to keep up with the virus in terms of its ability to develop resistance, Mellors said.

The cocktail of drugs that since the mid-1990s has transformed the HIV-AIDS infection from a death sentence to a chronic illness is about to expand, some 4,000 AIDS specialists gathered here for the week-long conference were told.

The pipeline of new antiretrovirals is fuller than it has been for a long time. It's a bumper crop, Mellors said.

Researchers are testing drugs that would prevent the virus from attacking human cells and growing inside the body, Mellors said. Six such drugs are ready for human testing and another dozen are almost ready for clinical tests, he said.

The next antiretroviral agent that's likely to be approved, the T-20, already has a backup that has been specifically designed to inhibit T-20 resistant virus, Mellors said.

So we have a drug that is not yet approved and we have a backup, should resistance develop to that drug, he said.

Anti-AIDS therapies have become simpler and their success rates have improved to 75-85 percent from 50-60 percent only a few years ago, Mellors said. They are approaching the ease with which we are treating common diseases like hypertension, Mellors said.

Today, instead of 10 to 20 pills taken twice or three times a day, therapies consist of two or three pills taken in the morning or evening, or one pill taken twice a day, he said. The simplicity is all the more important because it allows treatment in developing nations, he said.

"HAART (Highly active antiretroviral therapy) can be given in a hut, which makes it very effective at fighting AIDS in developing nations, Mellors said.

Meanwhile experimental vaccine therapies have yielded encouraging results.

By specifically boosting immune defenses against the HIV virus, the therapies would enable patients to interrupt the exhausting antiretroviral treatments. On Wednesday, the National French Agency for AIDS Research (ANRS), will present the results of two studies that it conducted on experimental vaccine therapies. The studies found that 25 percent of subjects who received the vaccine therapy could stop their antiretroviral treatment.

There is a real demand (for such cessations) because a lot of patients get exhausted by their treatment, the ANRS said.

In order to determine how the long the effect will last, the patients will be monitored for two years, said Michel Kazatchkine, director of ANRS.(Source: SAPA-AFP, 12 February 2003

Keywords	This Item is associated with the Following Keywords: .
You Can Comment on this Item, or View other people's Comments
Easy Print  Email to a friend

	Related News
	Daily anti-HIV pill could save millions (2007-09-21) An end to HIV? (2007-07-20) GM Viruses May Help Cure Hepatitis B Infections (2006-10-20) Radical AIDS drug set for launch in 2003 (2001-08-16) Wits therapy lifts hope for hepatitis B patients (2002-07-18)

	Related Publications
	Nothing new: responses to the introduction of antiretroviral drugs in South Africa (2006-09-28) Scaling up antiretroviral therapy in resource-limited settings: Treatment guidelines for a public health approach (2004-03-31) Anti-Retroviral Therapy in South Africa - A pocket guide of the prevention and management of Side Effects and Drug Interactions (2004-10-12) Introducing Antiretroviral Therapy (ART) on a Large Scale: Hope and Caution (2004-03-31) HIV/AIDS and Health Sector Responses in South Africa: Treatment Access and Equity - Balancing the Act (2004-02-20)

	Related Health Statistics
	Male urethral discharge incidence (0000-00-00) HIV prevalence (%) (antenatal) (2004-10-04) AIDS orphans (2005-04-20) Primary drug of abuse as % of all drugs of abuse (2007-05-21) Human development index (2004-02-09)

	Related Events
	International HIV/AIDS Treatment Education and Advocacy Summit (2000-03-13) International Conference on HIV/AIDS, Food and Nutrition Security (2005-04-14) Priorities in AIDS Care and Treatment Conference (2005-04-19) 2nd African Conference on Social Aspects of HIV/AIDS Research (2004-05-09) Training Course on Drug and Therapeutic Committees (2001-10-18)

	Related links
	AIDS Treatment News AIDS Law Project XIII International AIDS Conference (AIDS 2000) MSF Campaign for Access to Essential Medicines National Conference on HIV/AIDS in Botswana

	Related Content
	Treatment Monitor: Displaced Persons and Access to Treatment (2008-02-14) Treatment Monitor: Sexual and Reproductive Intentions (2008-02-14) Summary Bulletin 8 - DHS-LG Discussion List (2004-07-16) Treatment Monitor: Treatment as part of a continuum of care (2007-07-11) Treatment Monitor: Focus on Human Resources (2008-02-14)